vTv Therapeutics Inc. (VTVT)

NASDAQ: VTVT · IEX Real-Time Price · USD
1.25
+0.01 (0.81%)
At close: Aug 11, 2022 4:00 PM
1.20
-0.05 (-4.00%)
Pre-market: Aug 12, 2022 8:00 AM EDT
0.81%
Market Cap 96.66M
Revenue (ttm) 5.02M
Net Income (ttm) -15.75M
Shares Out 77.33M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 326,698
Open 1.30
Previous Close 1.24
Day's Range 1.24 - 1.30
52-Week Range 0.38 - 2.17
Beta -1.37
Analysts Buy
Price Target 4.25 (+240.0%)
Earnings Date Aug 3, 2022

About VTVT

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule... [Read more...]

Industry Biotechnology
IPO Date Jul 30, 2015
CEO Stephen Holcombe
Employees 9
Stock Exchange NASDAQ
Ticker Symbol VTVT
Full Company Profile

Financial Performance

In 2021, VTVT's revenue was $4.01 million, a decrease of -37.56% compared to the previous year's $6.41 million. Losses were -$12.99 million, 52.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is 4.25, which is an increase of 240.00% from the latest price.

Price Target
$4.25
(240.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type...

vTv Therapeutics Announces Investment by CinRx Pharma

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidia...

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Stu...

Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D Results confirmed TTP399 improves glycemia withou...

vTv Therapeutics (VTVT) Stock Surges 41% on Major Investment News

vTv Therapeutics (VTVT) stock is taking off on Wednesday after entering into a funding and collaboration agreement with G42 Investments. The post vTv Therapeutics (VTVT) Stock Surges 41% on Major Invest...

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 He...

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd...

7 Mighty Micro-Cap Stocks That Could Be Future Moonshots

These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. The post 7 Mighty Micro-Cap Stocks That Could Be Future Moonshots appeared fir...

Other symbols: CNTYCSSEEGYHROWJOB

3 Oversold Biotech Stocks to Buy Now

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

Other symbols: ALRNNVAX

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress...

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

HIGH POINT, N.C. , March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on...

vTv Therapeutics Announces CEO Transition

HIGH POINT, N.C., March 3, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 di...

vTv Therapeutics Shares Updated Corporate Presentation

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, ...

3 Stocks That Can Make You Rich in Just a Few Years

Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.

Other symbols: EMBKSDGR

vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%

vTv Therapeutics Inc (NASDAQ: VTVT) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here.

Dow Jones Newswires: VTv Therapeutics slashes 65% of workforce, focuses on its diabetes drug

VTv Therapeutics Inc. said it reduced its workforce by about 65% as it prioritizes development of diabetes drug TTP399.

Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...

VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 71.43% and 130.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the pro...

Earnings Preview: vTv Therapeutics (VTVT) Q3 Earnings Expected to Decline

VTv Therapeutics (VTVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

vTv Therapeutics Announces Deepa Prasad as New President and CEO

HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 di...

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with ...

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels

vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile

​​​​​vTv Therapeutics Inc (NASDAQ: VTVT) announced the results of a multiple ascending dose study evaluating HPP737 in healthy adults. HPP737 is an orally administered phosphodiesterase type 4 (PDE4) in...

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inh...

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects

7 Penny Stocks Waiting on The FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPl...

Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...